Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

This analysis of data from an open-label, nonrandomized, multicohort study of patients from the VE-BASKET trial evaluates the efficacy and safety of vemurafenib in the treatment of adults with BRAF V600–mutant Erdheim-Chester disease or Langerhans cell histiocytosis.

http://ift.tt/2AIb9Aw